VivoSeq
Neurology

Psychosis Associated With Alzheimer's Disease

2

Pipeline Programs↗

2

Active Trials↗

4

Companies Involved↗

Psychosis Associated With Alzheimer's Disease is an early-stage landscape with 2 programs across 4 companies. The most active players are Eli Lilly, Bristol-Myers Squibb, Karuna Therapeutics. 1 program is in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

21/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Eli Lilly logo

Eli Lilly

1 program

Phase 2Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 3K

Karuna Therapeutics

0 programs

PreclinicalK

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 21

ITI-1284

Intra-Cellular Therapies, Inc.

Phase 31

Karxt

Bristol-Myers Squibb

Approved
No programs

Analysis

Trial Status

2

clinical trials

Recruiting2 · 100%

Clinical Trials

Trial Activity

A Multicenter, Randomized, Double-blind, Placebo-controlled, Flexible-dose Study to Assess the Efficacy, Safety, and Tolerability of ITI-1284 in Patients With Psychosis Associated With Alzheimer's Disease
Recruiting·IIntra-Cellular Therapies, Inc.·Phase 2·NCT06540833·370 enrolled
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
Recruiting·KKaruna Therapeutics·Phase 3·NCT05980949·1,000 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)